Scarica l'app Stockscreener
100.39
0.44%
-0.44
Pre-mercato:
99.77
-0.62
-0.62%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Precedente Chiudi:
$100.83
Aprire:
$101.38
Volume 24 ore:
699.72K
Relative Volume:
1.10
Capitalizzazione di mercato:
$4.94B
Reddito:
$338.46M
Utile/perdita netta:
$-310.96M
Rapporto P/E:
-15.37
EPS:
-6.53
Flusso di cassa netto:
$-132.82M
1 W Prestazione:
-8.47%
1M Prestazione:
-2.87%
6M Prestazione:
-2.02%
1 anno Prestazione:
+16.02%
Intervallo 1D:
$99.38
$102.15
Intervallo di 1 settimana:
$99.38
$110.19
Portata 52W:
$72.21
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Nome
Axsome Therapeutics Inc
Settore
Industria
Telefono
(212) 332-3241
Indirizzo
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Confronta AXSM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
100.39 | 4.96B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-03 | Ripresa | Morgan Stanley | Overweight |
| 2025-06-03 | Iniziato | Oppenheimer | Outperform |
| 2025-04-07 | Iniziato | Jefferies | Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-12-31 | Reiterato | Mizuho | Outperform |
| 2024-09-03 | Iniziato | Wells Fargo | Overweight |
| 2024-08-06 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-04-29 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | Iniziato | Robert W. Baird | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2024-01-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-08-08 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-01-05 | Iniziato | Piper Sandler | Neutral |
| 2022-11-01 | Iniziato | Loop Capital | Buy |
| 2022-09-07 | Ripresa | Mizuho | Buy |
| 2021-08-10 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | Iniziato | Berenberg | Buy |
| 2021-01-08 | Iniziato | Jefferies | Buy |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-09-29 | Iniziato | BofA Securities | Underperform |
| 2020-09-10 | Iniziato | Morgan Stanley | Overweight |
| 2020-04-28 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-14 | Iniziato | Cowen | Outperform |
| 2019-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-17 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-16 | Reiterato | Guggenheim | Buy |
| 2019-10-16 | Iniziato | Guggenheim | Buy |
| 2019-09-18 | Iniziato | William Blair | Outperform |
| 2019-05-28 | Iniziato | SunTrust | Buy |
| 2019-05-23 | Reiterato | H.C. Wainwright | Buy |
| 2019-04-08 | Iniziato | SVB Leerink | Outperform |
| 2019-03-15 | Reiterato | H.C. Wainwright | Buy |
| 2016-10-03 | Ripresa | Brean Capital | Buy |
| 2015-12-15 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-12-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
Axsome Therapeutics Inc.’s Price Action Aligns with Quant SignalsTriple Digit Return Stock Predictions Released - metal.it
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
What makes Axsome Therapeutics Inc. stock price move sharplyStock Strategy Planner To Watch Now - jammulinksnews.com
Envestnet Asset Management Inc. Sells 10,086 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics (AXSM) to Release Earnings on Monday - MarketBeat
Why is Axsome Therapeutics Inc. stock attracting strong analyst attentionAchieve rapid portfolio growth with expert guidance - jammulinksnews.com
Royce & Associates LP Sells 6,743 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
What catalysts could drive Axsome Therapeutics Inc. stock higher in 2025Invest confidently with real-time data analysis - jammulinksnews.com
Does Axsome Therapeutics Inc. stock perform well during market downturnsGet timely alerts on market opportunities - jammulinksnews.com
Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Cwm LLC Trims Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Y Intercept Hong Kong Ltd Makes New $1.49 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
How strong is Axsome Therapeutics Inc. company’s balance sheetFree Market Dynamics Reports - jammulinksnews.com
Axsome Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayFree Stock Market Query - metal.it
Published on: 2025-07-27 23:41:07 - jammulinksnews.com
Is Axsome Therapeutics Inc. stock overvalued or undervaluedDynamic profit expansion - jammulinksnews.com
When is Axsome Therapeutics Inc. stock expected to show significant growth - jammulinksnews.com
How does Axsome Therapeutics Inc. generate profit in a changing economyUnprecedented profit potential - jammulinksnews.com
Knights of Columbus Asset Advisors LLC Sells 4,957 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Q3 EPS Estimate for Axsome Therapeutics Raised by Analyst - MarketBeat
Axsome Therapeutics: Navigating Setbacks with a Strong Pipeline and Analyst Confidence - AInvest
Axsome: Some Recent Setbacks, Some Recent Wins — Still A Buy (NASDAQ:AXSM) - Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) Shares Down 5.6%Here's Why - MarketBeat
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline - ADVFN Brasil
Why Axsome Therapeutics Inc. stock is on top investor watchlistsSuperior stock selection - jammulinksnews.com
What analysts say about Axsome Therapeutics Inc. stockOutstanding capital growth - Autocar Professional
Axsome Therapeutics Inc. Stock Analysis and ForecastRapid growth trajectories - PrintWeekIndia
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stake Raised by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. - MarketBeat
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM) - The Globe and Mail
New York State Common Retirement Fund Has $3.92 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Is Axsome Therapeutics Inc. stock overhyped or has real potentialUnstoppable trading performance - jammulinksnews.com
How high can Axsome Therapeutics Inc. stock price go in 2025Breakthrough investment results - jammulinksnews.com
How To Trade (AXSM) - news.stocktradersdaily.com
Axsome Therapeutics Settles SUNOSI (Solriamfetol) Patent Litigation With Hetero Labs Ltd. - 富途牛牛
Is This Stock a Buy After Soaring by 20% in 1 Day? - AOL.com
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now - MSN
Legato Capital Management LLC Buys New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today - 富途牛牛
Is Axsome Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
Leerink Partners Keeps Bullish Stance on Axsome Therapeutics with Buy Rating - AInvest
Lindbrook Capital LLC Cuts Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Optimistic Outlook for Axsome Therapeutics: Promising Pipeline and Potential Sales Growth Drive Buy Rating - TipRanks
Axsome Therapeutics Breaks Below 200-Day Moving AverageNotable for AXSM - Nasdaq
What drives Axsome Therapeutics Inc. stock priceUnprecedented profit potential - jammulinksnews.com
Readystate Asset Management LP Invests $6.95 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - The Globe and Mail
Axsome Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Axsome Therapeutics Inc Azioni (AXSM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Axsome Therapeutics Inc Azioni (AXSM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Murdock Hunter R. | General Counsel |
Jun 23 '25 |
Option Exercise |
29.91 |
6,014 |
179,879 |
6,014 |
| Murdock Hunter R. | General Counsel |
Jun 20 '25 |
Sale |
102.47 |
7,500 |
768,525 |
0 |
| Murdock Hunter R. | General Counsel |
Jun 23 '25 |
Sale |
100.12 |
6,014 |
602,122 |
0 |
1.32%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):